[{"orgOrder":0,"company":"DS Biopharma","sponsor":"Nuvothera","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Omega-3","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"DS Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"DS Biopharma \/ Nuvothera","highestDevelopmentStatusID":"12","companyTruncated":"DS Biopharma \/ Nuvothera"}]

Find Clinical Drug Pipeline Developments & Deals by DS Biopharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the terms of the agreement Nuvothera has acquired an option to exclusively licence rights to develop and commercialise EPADILIN® in the United States.

                          Brand Name : Epadilin

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          March 18, 2021

                          Lead Product(s) : Omega-3,Omega 6

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Sponsor : Nuvothera

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank